Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma

Abstract

Peer reviewed

Igor Puzanov, Mohammed M. Milhem, Robert Hans Ingemar Andtbacka, David R. Minor, Omid Hamid, Ai Li, Jeffrey Chou and Howard Kaufman

Journal of clinical oncology, Vol.33(15_suppl), pp.9063-9063

05/20/2015

DOI: 10.1200/jco.2015.33.15_suppl.9063

View Online

Title: Subtitle: Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma
Creators: Igor Puzanov - Vanderbilt University Medical Center
Mohammed M. Milhem - University of Iowa
Robert Hans Ingemar Andtbacka - University of Utah
David R. Minor - California Pacific Melanoma Center, San Francisco, CA
Omid Hamid - Angeles Clinic and Research Institute
Ai Li - Amgen
Jeffrey Chou - Amgen
Howard Kaufman - Rutgers, The State University of New Jersey
Resource Type: Abstract
Publication Details: Journal of clinical oncology, Vol.33(15_suppl), pp.9063-9063
DOI: 10.1200/jco.2015.33.15_suppl.9063
ISSN: 0732-183X
eISSN: 1527-7755
Language: English
Date published: 05/20/2015
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984363289902771

8 Record Views